1cP-MiPLA

Discovery

The parent compound MiPLA was first synthesized by Nichols and colleagues at Purdue University in 1994 during a systematic investigation of lysergamide structure-activity relationships.^[1] That study demonstrated MiPLA could fully substitute for LSD in trained rats, establishing its psychedelic activity in animal models despite reduced serotonin receptor affinity. 1cP-MiPLA has no published synthesis record in the academic literature; it likely emerged from clandestine laboratories applying the established 1-acyl prodrug strategy to the MiPLA scaffold.

The 1-acyl prodrug wave

1cP-MiPLA belongs to a wave of 1-acyl lysergamide prodrugs that appeared on research chemical markets from approximately 2015 onward. 1P-LSD was the first to receive detailed characterization,^[5] followed by 1B-LSD,^[6] 1cP-LSD,^[7] and 1V-LSD^[8] — each confirmed to release LSD as its active compound. 1cP-MiPLA extended this prodrug approach to a non-LSD parent for the first time, combining the 1-acyl mechanism with an alternative carboxamide.

First identification

1cP-MiPLA first appeared on online markets circa 2020.^[2] The compound was formally identified in 2022 when researchers at Japan's National Institute of Health Sciences detected it in seized blotter products, achieving structural elucidation through mass spectrometry and NMR.^[2] That 2023 publication remains the only peer-reviewed scientific report on 1cP-MiPLA, and its authors explicitly noted that the compound's metabolic pathways and biological activities had not been reported.^[2]

Structural class

1cP-MiPLA belongs to the lysergamide family — tetracyclic indole compounds built on the ergoline scaffold. It carries two modifications relative to LSD: a cyclopropanecarbonyl group at the N1-indole nitrogen (shared with 1cP-LSD) and an N-methyl-N-isopropyl substituent at the C-8 carboxamide (shared with MiPLA).^[2]

The C-8 amide position is a critical determinant of receptor affinity. Nichols and colleagues demonstrated that increasing alkyl bulk at this position progressively reduces serotonin receptor binding — MiPLA's mixed N-methyl-N-isopropyl group retains full LSD-like behavioral substitution but with 2–3× reduced potency.^[1]

Molecular properties

No CAS number has been assigned. The compound carries two carbonyl oxygens — one in the C-8 carboxamide and one in the N1-cyclopropanoyl group — and three nitrogen atoms distributed across the indole, the piperidine ring, and the carboxamide.

Stereochemistry

The ergoline scaffold contains two chirality centers at C-6a and C-9. The pharmacologically active configuration is (6aR,9R), corresponding to the d-lysergic acid series — the same absolute configuration as LSD. The opposite enantiomers are inactive at serotonin receptors.^[9]

Physical properties

No published characterization of 1cP-MiPLA's physical properties exists. Melting point, solubility, and stability data have not been reported. The compound has been encountered exclusively as blotter paper and tablet formulations.^[2] By analogy with other lysergamides, it is expected to be sensitive to heat, light, and oxidation.

1cP-MiPLA is presumed to function as a prodrug for MiPLA. The cyclopropanoyl group at the indole nitrogen renders the intact molecule largely inactive at serotonin receptors.^[10] Enzymes in blood and liver cleave this group, releasing MiPLA as the active compound.

This prodrug mechanism has been directly confirmed for five structurally related lysergamides, including 1cP-LSD → LSD,^[7] 1P-LSD → LSD,^[5] and 1V-LSD → LSD.^[8] Tanaka et al. explicitly stated that the metabolic pathways of 1cP-MiPLA have not been reported,^[2] but the consistency of this mechanism across the class provides strong structural-structural analog support.

Once released, MiPLA produces its psychedelic effects primarily through agonism at the 5-HT₂A receptor — the established mediator of classical psychedelic activity. In controlled LSD studies, the selective serotonin 2A receptor antagonist ketanserin completely abolishes all subjective effects.^[11] Additional activity at 5-HT₁A, 5-HT₂C, and dopaminergic systems contributes to the full pharmacological profile.^[12]

Pharmacokinetics

No pharmacokinetic data exist for 1cP-MiPLA or MiPLA in any species. Reference parameters from controlled LSD studies place oral absorption peak at approximately 1.1 hours, bioavailability at roughly 80%, and half-life at 2.7–3.5 hours.^[13][14]

Two structural differences distinguish 1cP-MiPLA from LSD in expected pharmacokinetic behavior. The prodrug hydrolysis step introduces an additional metabolic delay before active compound reaches circulation, consistent with delayed onset observed for 1cP-LSD relative to LSD.^[7] The altered carboxamide of MiPLA may further affect metabolic processing, but no data exist to characterize these differences.

Individuals who metabolize LSD slowly show approximately 75% higher blood levels and prolonged effects.^[15] Whether this genetic variation affects MiPLA metabolism is unknown.

Where it acts

As a presumed serotonin 2A receptor agonist, MiPLA (the active metabolite) is expected to trigger the classical serotonergic psychedelic cascade: activation of serotonin receptors on cortical neurons increases excitatory neurotransmission, disrupts the default mode network, and elevates global brain connectivity.^[12][16] In LSD imaging studies, these changes manifest as reduced filtering of sensory input and increased cross-talk between brain regions normally kept separate — the neural basis of the perceptual expansiveness characteristic of the psychedelic state.

MiPLA's preserved 5-HT₁A affinity^[1] suggests the modulatory, potentially anxiolytic component of the serotonergic response would be retained alongside the primary 5-HT₂A-driven effects.^[17]

Why it matters

The REBUS model (Relaxed Beliefs Under Psychedelics) proposes that 5-HT₂A activation loosens the brain's reliance on existing assumptions, allowing raw sensory experience to reshape perception and cognition. MiPLA's lower receptor affinity compared to LSD would predict a gentler version of this process — consistent with community reports of a shorter, more cognitively manageable experience.

LSD-class compounds also promote structural brain connectivity through neuroplasticity pathways. Whether MiPLA's reduced receptor binding preserves or diminishes this effect is unknown, with implications for any potential therapeutic application.

Toxicity

LSD has no known organ toxicity at any dose studied in humans.^[3] The estimated human lethal dose exceeds 14,000 µg — approximately 100× a strong recreational dose.^[3] Among five deaths historically attributed to LSD, none were credibly caused by direct drug toxicity.^[3] One documented accidental ingestion of approximately 55 mg (550× a standard dose) resulted in prolonged altered consciousness but complete recovery without organ damage.^[18]

Psychological risks

Acute psychological distress — anxiety, paranoia, thought loops, and panic — can occur at any dose, particularly in unsupportive settings or in individuals with pre-existing psychiatric vulnerability.^[11] Ego dissolution at high doses can be profoundly distressing without preparation and support.

Hallucinogen persisting perception disorder (HPPD) is a rare condition involving persistent visual disturbances — after-images, peripheral movement, halos, and visual haze / noise — following psychedelic use.^[4] LSD-type compounds are the most commonly implicated substances. Risk factors include prior psychiatric history and polydrug use.^[4] No HPPD cases have been specifically attributed to 1cP-MiPLA or MiPLA.

Psychedelic use can precipitate psychotic episodes in individuals with a personal or family history of schizophrenia spectrum disorders or bipolar disorder.safety citation needed

Tolerance and dependence

Classical serotonergic psychedelics develop rapid, near-complete tolerance after a single dose.^[19][20] The mechanism involves reduction of serotonin receptor density in the brain within 24 hours.^[20]

Full cross-tolerance exists between LSD and other classical psychedelics (psilocybin, mescaline) via the shared 5-HT₂A receptor mechanism.^[20][16] 1cP-MiPLA/MiPLA would be expected to participate in this cross-tolerance network.

Classical psychedelics are not considered habit-forming — they do not activate the brain's reward pathways in the manner of addictive substances.^[16] Community-reported tolerance parameters (near-immediate buildup, approximately 14-day full reset) are consistent with published LSD class data.

Drug interactions

No substance-specific interaction data exist for 1cP-MiPLA. All interaction assessments are extrapolated from LSD-class pharmacology.

Tramadol (dangerous): tramadol blocks serotonin reuptake in addition to its painkilling activity. Combining it with serotonergic psychedelics creates a risk of serotonin syndrome — a potentially fatal condition involving muscle rigidity, rapid heart rate, high fever, and altered consciousness.^[21] Deaths from tramadol combined with serotonergic agents have been reported.^[22]

MAOIs (dangerous): Monoamine oxidase inhibitors block serotonin breakdown, amplifying the effects of any serotonin-active compound. The combination of MAOIs with serotonergic substances has produced fatalities.^[22]

Lithium: Case reports suggest increased seizure risk when lithium is combined with psychedelics.safety citation needed

SSRIs/SNRIs: These antidepressants typically blunt psychedelic effects through receptor competition. Theoretical serotonin syndrome risk exists at high doses, though clinical significance for lysergamides specifically is unclear.safety citation needed

Cannabis (unknown): No published interaction data exist for 1cP-MiPLA combined with cannabis. The combination has not been characterized in controlled studies.

Contraindications

The following contraindications are inferred from the LSD class. No substance-specific data exist for 1cP-MiPLA.

Personal or family history of psychosis or schizophrenia spectrum disorders (absolute): Serotonin receptor activation can trigger or worsen psychotic episodes in vulnerable individuals.safety citation needed

Bipolar disorder (absolute): Risk of triggering manic episodes.safety citation needed

Concurrent tramadol use (absolute): Serotonin syndrome risk.^[21]

Concurrent MAOI use (absolute): Serotonin syndrome risk.^[22]

Heart conditions (relative): Serotonergic psychedelics produce mild increases in heart rate and blood pressure. While clinically insignificant in healthy individuals, these effects may be poorly tolerated by those with pre-existing cardiovascular conditions.safety citation needed

Pregnancy (absolute): No reproductive safety data exist for 1cP-MiPLA, MiPLA, or LSD.safety citation needed

As of 2026, 1cP-MiPLA is not widely scheduled by name in international drug control frameworks. Its legal status is complicated by its dual identity as a novel psychoactive substance and a presumed prodrug for MiPLA, which is itself structurally related to LSD. Jurisdictions with broad structural analog laws or blanket NPS legislation may capture it without explicit scheduling. All legal data below are web-retrieved and have not been verified against primary legislative texts.citation needed

Analog and prodrug considerations

The prodrug strategy underlying the 1-acyl lysergamide class has been explicitly described as a regulatory circumvention mechanism in forensic literature.^[23] 1cP-MiPLA's dual modification — N1-acylation plus an altered carboxamide — increases its structural distance from LSD compared to simpler analogs like 1P-LSD or 1cP-LSD, potentially complicating prosecution under analog laws.

This structural distance does not, however, affect classification under blanket NPS legislation that operates independently of structural similarity.